Accelerating drug development for neuroblastoma - New Drug
Development Strategy: an Innovative Therapies for Children with
Cancer, European Network for Cancer Research in Children and
Adolescents and International Society of Paediatric Oncology
Europe Neuroblastoma project

J 2017

Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project

MORENO, L., H. CARON, B. GEOERGER, A. EGGERT, G. SCHLEIERMACHER et. al.

Základní údaje

Originální název

Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project

Autoři

MORENO, L. (826 Velká Británie a Severní Irsko), H. CARON (756 Švýcarsko), B. GEOERGER (250 Francie), A. EGGERT (276 Německo), G. SCHLEIERMACHER (250 Francie), P. BROCK (826 Velká Británie a Severní Irsko), D. VALTEAU-COUANET (276 Německo), L. CHESLER (826 Velká Británie a Severní Irsko), J.H. SCHULTE (276 Německo), K. DE PRETER (56 Belgie), J. MOLENAAR (528 Nizozemské království), A. SCHRAMM (276 Německo), M. EILERS (276 Německo), T. VAN MAERKEN (56 Belgie), J.I. JOHNSEN (752 Švédsko), M. GARRETT (826 Velká Británie a Severní Irsko), S.L. GEORGE (826 Velká Británie a Severní Irsko), D.A. TWEDDLE (36 Austrálie), P. KOGNER (752 Švédsko), F. BERTHOLD (276 Německo), J. KOSTER (528 Nizozemské království), G. BARONE (826 Velká Británie a Severní Irsko), E.R. TUCKER (826 Velká Británie a Severní Irsko), L. MARSHALL (826 Velká Británie a Severní Irsko), R. HEROLD (826 Velká Británie a Severní Irsko), Jaroslav ŠTĚRBA (203 Česká republika, garant, domácí), K. NORGA (56 Belgie), G. VASSAL (250 Francie) a A.D.J. PEARSON (826 Velká Británie a Severní Irsko)

Vydání

EXPERT OPINION ON DRUG DISCOVERY, ABINGDON, TAYLOR & FRANCIS LTD, 2017, 1746-0441

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.692

Kód RIV

RIV/00216224:14110/17:00098862

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1080/17460441.2017.1340269

UT WoS

000405392700004

Klíčová slova anglicky

Neuroblastoma; drug development; phase I; preclinical testing; clinical trials

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 28. 1. 2021 11:23, Mgr. Tereza Miškechová

Anotace

V originále

Introduction: Neuroblastoma, the commonest paediatric extra-cranial tumour, remains a leading cause of death from cancer in children. There is an urgent need to develop new drugs to improve cure rates and reduce long-term toxicity and to incorporate molecularly targeted therapies into treatment. Many potential drugs are becoming available, but have to be prioritised for clinical trials due to the relatively small numbers of patients. Areas covered: The current drug development model has been slow, associated with significant attrition, and few new drugs have been developed for neuroblastoma. The Neuroblastoma New Drug Development Strategy (NDDS) has: 1) established a group with expertise in drug development; 2) prioritised targets and drugs according to tumour biology (target expression, dependency, pre-clinical data; potential combinations; biomarkers), identifying as priority targets ALK, MEK, CDK4/6, MDM2, MYCN (druggable by BET bromodomain, aurora kinase, mTORC1/2) BIRC5 and checkpoint kinase 1; 3) promoted clinical trials with target-prioritised drugs. Drugs showing activity can be rapidly transitioned via parallel randomised trials into front-line studies. Expert opinion: The Neuroblastoma NDDS is based on the premise that optimal drug development is reliant on knowledge of tumour biology and prioritisation. This approach will accelerate neuroblastoma drug development and other poor prognosis childhood malignancies.

Návaznosti

LM2015090, projekt VaV

Název: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Akronym: CZECRIN)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZECRIN - Český národní uzel Evropské sítě infrastruktur klinického výzkumu

Citovat

MORENO, L., H. CARON, B. GEOERGER, A. EGGERT, G. SCHLEIERMACHER, P. BROCK, D. VALTEAU-COUANET, L. CHESLER, J.H. SCHULTE, K. DE PRETER, J. MOLENAAR, A. SCHRAMM, M. EILERS, T. VAN MAERKEN, J.I. JOHNSEN, M. GARRETT, S.L. GEORGE, D.A. TWEDDLE, P. KOGNER, F. BERTHOLD, J. KOSTER, G. BARONE, E.R. TUCKER, L. MARSHALL, R. HEROLD, Jaroslav ŠTĚRBA, K. NORGA, G. VASSAL a A.D.J. PEARSON. Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. EXPERT OPINION ON DRUG DISCOVERY. ABINGDON: TAYLOR & FRANCIS LTD, 2017, roč. 12, č. 8, s. 801-811. ISSN 1746-0441. Dostupné z: https://dx.doi.org/10.1080/17460441.2017.1340269.

@article{1399958,
   author = {Moreno, L. and Caron, H. and Geoerger, B. and Eggert, A. and Schleiermacher, G. and Brock, P. and ValteauandCouanet, D. and Chesler, L. and Schulte, J.H. and De Preter, K. and Molenaar, J. and Schramm, A. and Eilers, M. and Van Maerken, T. and Johnsen, J.I. and Garrett, M. and George, S.L. and Tweddle, D.A. and Kogner, P. and Berthold, F. and Koster, J. and Barone, G. and Tucker, E.R. and Marshall, L. and Herold, R. and Štěrba, Jaroslav and Norga, K. and Vassal, G. and Pearson, A.D.J.},
   article_location = {ABINGDON},
   article_number = {8},
   doi = {http://dx.doi.org/10.1080/17460441.2017.1340269},
   keywords = {Neuroblastoma; drug development; phase I; preclinical testing; clinical trials},
   language = {eng},
   issn = {1746-0441},
   journal = {EXPERT OPINION ON DRUG DISCOVERY},
   title = {Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project},
   url = {http://dx.doi.org/10.1080/17460441.2017.1340269},
   volume = {12},
   year = {2017}
}

TY  - JOUR
ID  - 1399958
AU  - Moreno, L. - Caron, H. - Geoerger, B. - Eggert, A. - Schleiermacher, G. - Brock, P. - Valteau-Couanet, D. - Chesler, L. - Schulte, J.H. - De Preter, K. - Molenaar, J. - Schramm, A. - Eilers, M. - Van Maerken, T. - Johnsen, J.I. - Garrett, M. - George, S.L. - Tweddle, D.A. - Kogner, P. - Berthold, F. - Koster, J. - Barone, G. - Tucker, E.R. - Marshall, L. - Herold, R. - Štěrba, Jaroslav - Norga, K. - Vassal, G. - Pearson, A.D.J.
PY  - 2017
TI  - Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project
JF  - EXPERT OPINION ON DRUG DISCOVERY
VL  - 12
IS  - 8
SP  - 801-811
EP  - 801-811
PB  - TAYLOR & FRANCIS LTD
SN  - 17460441
KW  - Neuroblastoma
KW  - drug development
KW  - phase I
KW  - preclinical testing
KW  - clinical trials
UR  - http://dx.doi.org/10.1080/17460441.2017.1340269
L2  - http://dx.doi.org/10.1080/17460441.2017.1340269
N2  - Introduction: Neuroblastoma, the commonest paediatric extra-cranial tumour, remains a leading cause of death from cancer in children. There is an urgent need to develop new drugs to improve cure rates and reduce long-term toxicity and to incorporate molecularly targeted therapies into treatment. Many potential drugs are becoming available, but have to be prioritised for clinical trials due to the relatively small numbers of patients. Areas covered: The current drug development model has been slow, associated with significant attrition, and few new drugs have been developed for neuroblastoma. The Neuroblastoma New Drug Development Strategy (NDDS) has: 1) established a group with expertise in drug development; 2) prioritised targets and drugs according to tumour biology (target expression, dependency, pre-clinical data; potential combinations; biomarkers), identifying as priority targets ALK, MEK, CDK4/6, MDM2, MYCN (druggable by BET bromodomain, aurora kinase, mTORC1/2) BIRC5 and checkpoint kinase 1; 3) promoted clinical trials with target-prioritised drugs. Drugs showing activity can be rapidly transitioned via parallel randomised trials into front-line studies. Expert opinion: The Neuroblastoma NDDS is based on the premise that optimal drug development is reliant on knowledge of tumour biology and prioritisation. This approach will accelerate neuroblastoma drug development and other poor prognosis childhood malignancies.
ER  -

MORENO, L., H. CARON, B. GEOERGER, A. EGGERT, G. SCHLEIERMACHER, P. BROCK, D. VALTEAU-COUANET, L. CHESLER, J.H. SCHULTE, K. DE PRETER, J. MOLENAAR, A. SCHRAMM, M. EILERS, T. VAN MAERKEN, J.I. JOHNSEN, M. GARRETT, S.L. GEORGE, D.A. TWEDDLE, P. KOGNER, F. BERTHOLD, J. KOSTER, G. BARONE, E.R. TUCKER, L. MARSHALL, R. HEROLD, Jaroslav ŠTĚRBA, K. NORGA, G. VASSAL a A.D.J. PEARSON. Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. \textit{EXPERT OPINION ON DRUG DISCOVERY}. ABINGDON: TAYLOR \&{} FRANCIS LTD, 2017, roč.~12, č.~8, s.~801-811. ISSN~1746-0441. Dostupné z: https://dx.doi.org/10.1080/17460441.2017.1340269.

Podrobný výpis o publikaci